ABR167

ABR167 is a small protein antagonist (approximately 5 kDa) that targets the human interleukin-22 receptor alpha (IL-22R1). Developed using directed evolution from an albumin-binding domain (ABD) scaffold of streptococcal protein G, ABR167 blocks the interaction between the cytokine IL-22 and its high-affinity receptor subunit IL-22R1. By inhibiting this signaling axis, ABR167 prevents the recruitment of pathologic effector cells and reduces tissue damage associated with chronic inflammation. In preclinical murine models of dextran sulfate sodium (DSS)-induced colitis, ABR167 demonstrated the ability to suppress clinical and histological markers of intestinal inflammation, including the reduction of pro-inflammatory cytokines such as IL-1β, IL-6, and IL-17A. It is being investigated as a potential therapeutic lead for inflammatory bowel diseases (IBD) such as ulcerative colitis.

Other names

ABR ligandABD-derived IL-22R1 blocker